Psoriasis Treatment Market by Drug Class [Tumour Necrosis Factor Inhibitors (Adalimumab, Infliximab and Etanercept), Interleukin-Inhibitors (Ustekinumab, Secukinumab, Ixekizumab and Brodalumab), Vitamin D Analogues (Calcitriol, Calcipotriol and Tacalcitol)], Treatment Type {Topicals [Over-the-counter (OTC) Topicals, Topical Non-Steroids and Topical Steroids], Systemic (Retinoid, Cyclosporine and Methotrexate), Biologics [Tumour Necrosis Factor Alpha (TNF-α) Inhibitors, Interleukin 12 and 23 (IL-12/23) Inhibitors, Interleukin 17 (IL-17) Inhibitor, T cell Inhibitor]} - Forecast till 2027Market SnapshotAs per the analysis by Market Research Future Reports (MRFR), the global psoriasis treatment market is anticipated to garner the market value of USD 13.1 billion, expanding at a CAGR of 7.3% during the assessment period from 2019 to 2025.The psoriasis condition is estimated to be driven by environmental and genetic factors.
The psoriasis treatment market 2020 is predicted to be majorly boosted by the rising awareness regarding the treatment, along with better healthcare infrastructure.
Further, the adoption of a sedentary lifestyle, increased alcohol consumption, smoking, and an unhealthy diet are some of the other vital factors augmenting the global market.
Nevertheless, the growing adoption of alternative psoriasis treatments and the prevailing competition among the key players is projected to enhance the psoriasis treatment market considerably.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/2769 Market SegmentationThe segment evaluation of the global psoriasis treatment market is done by treatment type and drug class.The global market for psoriasis treatment, by drug class, is segmented into Interleukin-inhibitors, tumor necrosis factor inhibitors, and vitamin D analogs.
Moreover, tumor necrosis factor inhibitors are segmented into infliximab, adalimumab, and etanercept.
Vitamin D analogs are segmented into calcipotriol, calcitriol, and tacalcitol.The global market for psoriasis treatment, by treatment, is segmented into systemic, topicals, and biologics.